Jeffrey Settleman
Senior Vice President, Chief Scientific Officer, Oncology R&D Pfizer
Dr. Jeff Settleman is the Chief Scientific Officer for Oncology Research and Development and serves as the La Jolla site head. Jeff leads all oncology research from the beginning stages of discovery to proof-of-concept clinical studies.
Jeff is an internationally recognized leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug resistance, and personalized cancer medicine.
Jeff held numerous notable positions in both academic research and drug discovery before joining the Pfizer team. Prior to his current role, Jeff served as Distinguished Principal Investigator and Head of Oncology Research at Calico Life Sciences. Prior to Calico, Jeff led Discovery Oncology at Genentech.
Seminars
- Evaluating the landscape of ADC therapies: is the risk of innovation now lower than the risk of irrelevancy?
- Assessing hurdles and opportunities to achieve differentiated ADC profiles in crowded ADC payload and target fields
- Delving into novel ADC payloads: what new MoAs are emerging and what has been demonstrated so far?
- Understanding perspectives on the future of ADC development across ADC design, targeting, and precision medicine approaches
